M-ficolin levels reflect disease activity and predict remission in early rheumatoid arthritis

Christian Gytz Ammitzbøll; Steffen Thiel; Jens Christian Jensenius; Torkell Juulsgaad Ellingsen; Kim Hørslev-Petersen; Merete L Hetland; Michael Peter Junker; Niels Steen Krogh; Mikkel Østergaard; Kristian Stengaard-Pedersen

doi:10.1002/art.38179

M-ficolin levels reflect disease activity and predict remission in early rheumatoid arthritis

Christian Gytz Ammitzbøll, Steffen Thiel, Jens Christian Jensenius, Torkell Juulsgaad Ellingsen, Kim Hørslev-Petersen, Merete L Hetland, Michael Peter Junker, Niels Steen Krogh, Mikkel Østergaard, Kristian Stengaard-Pedersen

Department of Clinical Medicine

14 Citations (Scopus)

Abstract

Objective To assess plasma M-ficolin concentrations in disease-modifying antirheumatic drug (DMARD)-naive patients with early rheumatoid arthritis (RA), to investigate the correlation of M-ficolin concentrations with disease activity markers, and to determine the predictive value of M-ficolin with respect to the Disease Activity Score in 28 joints (DAS28). Methods The study group included 180 DMARD-naive patients with early RA who participated in a randomized controlled trial of methotrexate and intraarticular glucocorticoids plus either adalimumab or placebo/adalimumab. One hundred healthy control subjects and 51 patients with chronic RA were also assessed. A sandwich-type time-resolved fluorometric immunoassay was used for quantification of plasma M-ficolin. Results At baseline, M-ficolin levels were highest in the group of DMARD-naive patients with newly diagnosed active RA, and the level in these patients decreased 26% after 1 year of aggressive treatment. The baseline M-ficolin level correlated with 5 of 7 disease activity markers, including the DAS28 and the Health Assessment Questionnaire (HAQ), and a similar pattern of correlations was observed at 1 year. Multiple logistic regression analysis showed that an elevated M-ficolin level at baseline was the strongest predictor of not achieving either DAS28 remission (odds ratio [OR] 4.18, 95% confidence interval [95% CI] 2.02-8.63) or low disease activity (OR 2.45, 95% CI 1.13-5.28) at 1 year. The presence of a baseline M-ficolin level in the lowest quartile resulted in sensitivity of 29%, specificity of 93%, and positive predictive value of 95% for low disease activity at 1 year. Conclusion In patients with early RA, elevated plasma M-ficolin levels correlated with a high DAS28 and a high HAQ score at baseline and 1 year. A low M-ficolin level was the strongest predictor of remission and low disease activity in a multivariate analysis.

Original language	English
Journal	Arthritis & Rheumatism
Volume	65
Issue number	12
Pages (from-to)	3045–3050
Number of pages	6
ISSN	0004-3591
DOIs	https://doi.org/10.1002/art.38179
Publication status	Published - Dec 2013

Access to Document

10.1002/art.38179

Cite this

@article{6681c6517bad4aaaae16cc416fdeb8b9,

title = "M-ficolin levels reflect disease activity and predict remission in early rheumatoid arthritis",

abstract = "Objective To assess plasma M-ficolin concentrations in disease-modifying antirheumatic drug (DMARD)-naive patients with early rheumatoid arthritis (RA), to investigate the correlation of M-ficolin concentrations with disease activity markers, and to determine the predictive value of M-ficolin with respect to the Disease Activity Score in 28 joints (DAS28). Methods The study group included 180 DMARD-naive patients with early RA who participated in a randomized controlled trial of methotrexate and intraarticular glucocorticoids plus either adalimumab or placebo/adalimumab. One hundred healthy control subjects and 51 patients with chronic RA were also assessed. A sandwich-type time-resolved fluorometric immunoassay was used for quantification of plasma M-ficolin. Results At baseline, M-ficolin levels were highest in the group of DMARD-naive patients with newly diagnosed active RA, and the level in these patients decreased 26% after 1 year of aggressive treatment. The baseline M-ficolin level correlated with 5 of 7 disease activity markers, including the DAS28 and the Health Assessment Questionnaire (HAQ), and a similar pattern of correlations was observed at 1 year. Multiple logistic regression analysis showed that an elevated M-ficolin level at baseline was the strongest predictor of not achieving either DAS28 remission (odds ratio [OR] 4.18, 95% confidence interval [95% CI] 2.02-8.63) or low disease activity (OR 2.45, 95% CI 1.13-5.28) at 1 year. The presence of a baseline M-ficolin level in the lowest quartile resulted in sensitivity of 29%, specificity of 93%, and positive predictive value of 95% for low disease activity at 1 year. Conclusion In patients with early RA, elevated plasma M-ficolin levels correlated with a high DAS28 and a high HAQ score at baseline and 1 year. A low M-ficolin level was the strongest predictor of remission and low disease activity in a multivariate analysis.",

author = "Ammitzb{\o}ll, {Christian Gytz} and Steffen Thiel and Jensenius, {Jens Christian} and Ellingsen, {Torkell Juulsgaad} and Kim H{\o}rslev-Petersen and Hetland, {Merete L} and Junker, {Michael Peter} and Krogh, {Niels Steen} and Mikkel {\O}stergaard and Kristian Stengaard-Pedersen",

year = "2013",

month = dec,

doi = "10.1002/art.38179",

language = "English",

volume = "65",

pages = "3045–3050",

journal = "Arthritis & Rheumatology",

issn = "2326-5205",

publisher = "Wiley",

number = "12",

}

TY - JOUR

T1 - M-ficolin levels reflect disease activity and predict remission in early rheumatoid arthritis

AU - Ammitzbøll, Christian Gytz

AU - Thiel, Steffen

AU - Jensenius, Jens Christian

AU - Ellingsen, Torkell Juulsgaad

AU - Hørslev-Petersen, Kim

AU - Hetland, Merete L

AU - Junker, Michael Peter

AU - Krogh, Niels Steen

AU - Østergaard, Mikkel

AU - Stengaard-Pedersen, Kristian

PY - 2013/12

Y1 - 2013/12

N2 - Objective To assess plasma M-ficolin concentrations in disease-modifying antirheumatic drug (DMARD)-naive patients with early rheumatoid arthritis (RA), to investigate the correlation of M-ficolin concentrations with disease activity markers, and to determine the predictive value of M-ficolin with respect to the Disease Activity Score in 28 joints (DAS28). Methods The study group included 180 DMARD-naive patients with early RA who participated in a randomized controlled trial of methotrexate and intraarticular glucocorticoids plus either adalimumab or placebo/adalimumab. One hundred healthy control subjects and 51 patients with chronic RA were also assessed. A sandwich-type time-resolved fluorometric immunoassay was used for quantification of plasma M-ficolin. Results At baseline, M-ficolin levels were highest in the group of DMARD-naive patients with newly diagnosed active RA, and the level in these patients decreased 26% after 1 year of aggressive treatment. The baseline M-ficolin level correlated with 5 of 7 disease activity markers, including the DAS28 and the Health Assessment Questionnaire (HAQ), and a similar pattern of correlations was observed at 1 year. Multiple logistic regression analysis showed that an elevated M-ficolin level at baseline was the strongest predictor of not achieving either DAS28 remission (odds ratio [OR] 4.18, 95% confidence interval [95% CI] 2.02-8.63) or low disease activity (OR 2.45, 95% CI 1.13-5.28) at 1 year. The presence of a baseline M-ficolin level in the lowest quartile resulted in sensitivity of 29%, specificity of 93%, and positive predictive value of 95% for low disease activity at 1 year. Conclusion In patients with early RA, elevated plasma M-ficolin levels correlated with a high DAS28 and a high HAQ score at baseline and 1 year. A low M-ficolin level was the strongest predictor of remission and low disease activity in a multivariate analysis.

AB - Objective To assess plasma M-ficolin concentrations in disease-modifying antirheumatic drug (DMARD)-naive patients with early rheumatoid arthritis (RA), to investigate the correlation of M-ficolin concentrations with disease activity markers, and to determine the predictive value of M-ficolin with respect to the Disease Activity Score in 28 joints (DAS28). Methods The study group included 180 DMARD-naive patients with early RA who participated in a randomized controlled trial of methotrexate and intraarticular glucocorticoids plus either adalimumab or placebo/adalimumab. One hundred healthy control subjects and 51 patients with chronic RA were also assessed. A sandwich-type time-resolved fluorometric immunoassay was used for quantification of plasma M-ficolin. Results At baseline, M-ficolin levels were highest in the group of DMARD-naive patients with newly diagnosed active RA, and the level in these patients decreased 26% after 1 year of aggressive treatment. The baseline M-ficolin level correlated with 5 of 7 disease activity markers, including the DAS28 and the Health Assessment Questionnaire (HAQ), and a similar pattern of correlations was observed at 1 year. Multiple logistic regression analysis showed that an elevated M-ficolin level at baseline was the strongest predictor of not achieving either DAS28 remission (odds ratio [OR] 4.18, 95% confidence interval [95% CI] 2.02-8.63) or low disease activity (OR 2.45, 95% CI 1.13-5.28) at 1 year. The presence of a baseline M-ficolin level in the lowest quartile resulted in sensitivity of 29%, specificity of 93%, and positive predictive value of 95% for low disease activity at 1 year. Conclusion In patients with early RA, elevated plasma M-ficolin levels correlated with a high DAS28 and a high HAQ score at baseline and 1 year. A low M-ficolin level was the strongest predictor of remission and low disease activity in a multivariate analysis.

U2 - 10.1002/art.38179

DO - 10.1002/art.38179

M3 - Journal article

C2 - 24022747

SN - 2326-5205

VL - 65

SP - 3045

EP - 3050

JO - Arthritis & Rheumatology

JF - Arthritis & Rheumatology

IS - 12

ER -

M-ficolin levels reflect disease activity and predict remission in early rheumatoid arthritis

Abstract

Access to Document

Fingerprint

Cite this